Lyka Labs Ltd.

BSE: LYKALABS500259ISIN INE933A01014

Healthcare
Pharmaceuticals

Share price

₹76.00+1.00 (+1.33%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹96.68
52W low: ₹44.49
Off 52W high: -21.39%
1M return: -3.01%
3M return: +9.67%
6M return: +28.62%
1Y return: -19.92%
20D avg volume: 5,888
50 DMA: ₹79.91
200 DMA: ₹68.48

Key ratios Consolidated

Market cap: ₹274.76 Cr
Current price: ₹76.00
52W high / low: ₹96.68 / ₹44.49
Face value: ₹10.00
P/E: -56.09
P/B: 2.87
EPS (TTM): ₹-1.36
Book value / share: ₹26.48
ROE: —
ROCE: -7.00%
Operating margin: —
Net margin: —
Debt / equity: 0.53
Net debt: ₹47.00 Cr
Interest cover: -2.54
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 90.5 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	44.20	42.31	28.03	30.73	36.66	33.03	33.43	33.80	41.16	30.11	27.77	32.56
	0.62	0.42	0.61	1.16	1.09	0.63	0.82	0.83	0.03	0.56	0.29	0.54
	44.82	42.73	28.64	31.89	37.75	33.66	34.25	34.62	41.18	30.67	28.06	33.11
	43.75	40.78	37.23	32.05	42.14	32.30	31.23	31.05	38.51	28.81	29.71	29.82
	13.57	11.20	7.43	7.33	8.97	8.05	9.68	9.42	10.20	7.78	8.64	9.02
	4.65	7.50	5.00	4.30	5.67	4.53	3.98	3.67	8.22	4.01	3.24	2.89
	12.58	11.49	12.91	9.49	10.40	9.05	9.61	8.48	8.35	8.19	7.23	7.17
	1.02	1.01	0.70	0.82	0.79	0.85	0.47	0.61	0.54	0.65	1.07	1.28
	2.05	2.01	2.04	2.15	2.15	2.11	1.42	1.83	1.76	1.76	2.90	2.84
	10.20	9.82	10.54	8.04	13.93	7.55	6.65	7.06	9.91	6.72	6.54	6.85
	1.07	1.95	-8.59	-0.16	-4.38	1.35	3.02	3.57	2.67	1.86	-1.65	3.29
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
	1.07	1.95	-8.59	-0.16	-4.38	1.35	3.02	3.57	2.67	1.86	-1.63	3.29
	-0.20	0.10	-0.52	-0.01	-1.17	0.36	0.99	0.87	0.76	0.57	0.46	1.27
	1.27	2.05	-8.07	-0.15	-3.21	1.00	2.03	2.70	2.10	1.29	-2.09	1.78
	0.36	0.57	-2.13	0.00	-0.94	0.25	0.49	0.75	0.58	0.40	-3.83	0.53
Key metrics
	4.14	4.97	-5.85	2.81	-1.44	4.31	4.91	6.01	4.97	4.27	2.34	7.41
	9.40%	11.70%	-20.90%	9.10%	-3.90%	13.00%	14.70%	17.80%	12.10%	14.20%	8.40%	22.80%
	2.90%	4.80%	-28.80%	-0.50%	-8.80%	3.00%	6.10%	8.00%	5.10%	4.30%	-7.50%	5.50%
	1.60%	—	-6.50%	—	-2.90%	—	2.70%	—	—	—	—	—
	20.60%	28.10%	-16.20%	-9.10%	-10.90%	9.70%	20.40%	3.80%	—	—	—	—
	139.60%	105.00%	-497.50%	-105.60%	-252.90%	-22.50%	197.10%	51.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	145.27	128.44	138.50	111.19	93.07	194.09
	2.81	3.50	2.23	1.46	3.40	2.09
	148.08	131.94	140.73	112.65	96.47	196.18
	153.81	143.72	129.60	113.17	102.25	130.41
	39.53	31.77	37.07	32.14	23.08	26.94
	21.45	19.50	19.88	13.49	15.69	26.45
	46.47	41.85	34.63	26.77	18.61	18.06
	3.55	3.33	2.27	4.89	11.87	20.13
	8.25	8.46	6.77	12.80	14.15	17.35
	38.60	39.88	30.34	23.86	20.07	21.90
	-5.73	-11.78	11.12	-0.52	-5.78	65.77
	0.00	0.00	0.00	-0.41	-7.39	-6.52
	-5.73	-11.78	11.12	-0.93	-13.17	59.25
	-0.63	-1.34	3.19	1.69	0.02	20.80
	-4.90	-10.44	7.93	-2.62	-13.15	39.00
	-1.20	-2.81	2.22	-0.79	-4.63	13.57
Key metrics
	6.07	0.01	20.16	16.76	12.85	96.73
	4.18%	0.00%	14.60%	15.10%	13.80%	49.80%
	-3.37%	-8.10%	5.70%	-2.40%	-14.10%	20.10%
	—	-7.00%	10.30%	—	—	—
	6.10%	-7.30%	24.60%	19.50%	-52.00%	—
	-294.44%	-231.70%	402.70%	80.10%	-133.70%	—
	—	-5.89	-13.75	—	—	—
	—	-0.50	0.24	—	—	—
	—	0.53	0.37	—	—	—
	—	47.00	36.59	—	—	—
	—	90.5	107.0	—	—	—
Balance sheet
	—	174.54	176.21	—	—	—
	—	63.28	67.43	—	—	—
	—	1.36	1.34	—	—	—
	—	35.03	43.08	—	—	—
	—	13.63	12.47	—	—	—
	—	7.65	5.37	—	—	—
	—	80.40	76.90	—	—	—
	—	16.79	14.95	—	—	—
	—	53.90	46.63	—	—	—
	—	48.36	37.93	—	—	—
	—	25.37	18.72	—	—	—
	—	22.99	19.21	—	—	—
	—	90.83	103.58	—	—	—
Cash flow
	—	5.24	1.90	—	—	—
	—	-9.41	-11.80	—	—	—
	—	4.19	5.29	—	—	—
	—	11.13	15.65	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	44.20	42.31	28.03	30.73	32.97	29.18	30.52	32.92	41.16	30.11	26.98	31.41
	0.59	0.42	0.51	1.26	1.22	0.67	0.72	0.87	0.13	0.62	0.39	0.53
	44.79	42.73	28.54	31.99	34.19	29.84	31.24	33.80	41.28	30.72	27.37	31.94
	43.67	40.73	35.43	31.71	38.98	28.67	28.97	30.21	38.02	28.38	28.57	29.54
	13.57	11.20	7.43	7.33	8.97	8.05	9.68	9.42	10.20	7.78	8.64	9.02
	4.65	7.50	5.00	4.30	3.25	2.25	2.10	3.20	8.22	4.00	2.68	2.97
	12.57	11.48	12.87	9.42	10.33	8.97	9.52	8.33	8.20	8.04	7.15	6.99
	1.02	1.01	0.87	0.82	0.79	0.85	0.52	0.62	0.52	0.65	1.03	1.26
	2.05	2.01	2.04	2.08	2.07	2.03	1.34	1.75	1.68	1.68	2.77	2.72
	10.14	9.79	8.61	7.84	13.34	6.36	6.40	6.91	9.67	6.52	6.22	6.81
	1.12	1.99	-6.89	0.28	-4.80	1.17	2.27	3.59	3.27	2.35	-1.20	2.40
	0.00	0.00	-23.01	0.00	0.00	0.00	0.00	—	—	—	-0.01	—
	1.12	1.99	-29.90	0.28	-4.80	1.17	2.27	3.59	3.27	2.35	-1.21	2.40
	-0.20	0.11	0.13	0.00	-1.17	0.36	0.97	0.89	0.80	0.60	0.41	1.04
	1.31	2.10	-29.77	0.28	-3.63	0.81	1.31	2.70	2.47	1.75	-1.62	1.36
	0.36	0.58	-8.50	0.08	-1.02	0.22	0.36	0.75	0.69	—	-0.50	0.40
Key metrics
	4.19	5.01	-26.99	3.18	-1.94	4.05	4.13	5.96	5.47	4.68	2.59	6.38
	9.50%	11.80%	-96.30%	10.30%	-5.90%	13.90%	13.50%	18.10%	13.30%	15.50%	9.60%	20.30%
	3.00%	5.00%	-106.20%	0.90%	-11.00%	2.80%	4.30%	8.20%	6.00%	5.80%	-6.00%	4.30%
	1.80%	—	-24.80%	—	-2.60%	—	1.70%	—	—	—	—	—
	34.10%	45.00%	-8.20%	-6.70%	-19.90%	-3.10%	13.10%	4.80%	—	—	—	—
	136.10%	159.30%	-2,372.50%	-89.60%	-247.00%	-53.70%	180.90%	98.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	145.27	120.91	134.70	106.40	80.59	164.35
	2.78	3.97	2.34	1.65	3.45	2.72
	148.05	124.88	137.04	108.04	84.04	167.07
	151.54	135.10	125.57	108.92	90.08	102.16
	39.53	31.77	37.07	32.14	23.08	26.94
	21.45	14.80	17.52	11.58	7.19	4.33
	46.34	41.60	34.09	26.01	17.48	16.22
	3.72	3.33	2.30	4.80	11.57	19.92
	8.18	8.46	6.45	12.29	13.52	15.39
	36.38	36.22	29.50	22.88	18.45	19.77
	-3.50	-10.22	11.47	-0.88	-6.03	64.91
	-23.01	-23.01	0.00	-0.06	-7.17	-4.67
	-26.51	-33.24	11.47	-0.93	-13.21	60.24
	0.04	-0.95	3.25	1.34	0.08	20.34
	-26.08	-32.29	8.23	-2.27	-13.29	39.90
	-7.48	-9.18	2.28	-0.72	-4.65	13.87
Key metrics
	-14.61	-21.45	20.22	16.16	11.88	95.55
	-10.06%	-17.70%	15.00%	15.20%	14.70%	58.10%
	-17.95%	-26.70%	6.10%	-2.10%	-16.50%	24.30%
	—	-25.50%	8.60%	—	—	—
	15.67%	-10.20%	26.60%	32.00%	-51.00%	—
	-2,291.60%	-492.30%	462.60%	82.90%	-133.30%	—
	—	-6.04	-12.43	—	—	—
	—	-0.16	0.40	—	—	—
	—	0.56	0.28	—	—	—
	—	47.17	36.61	—	—	—
	—	89.7	105.9	—	—	—
Balance sheet
	—	170.75	205.58	—	—	—
	—	60.45	66.12	—	—	—
	—	1.19	1.32	—	—	—
	—	32.91	40.45	—	—	—
	—	13.63	12.47	—	—	—
	—	7.12	4.70	—	—	—
	—	80.40	76.89	—	—	—
	—	16.79	13.83	—	—	—
	—	53.50	44.78	—	—	—
	—	48.36	37.93	—	—	—
	—	25.37	18.72	—	—	—
	—	22.99	19.21	—	—	—
	—	87.00	134.94	—	—	—
Cash flow
	—	5.09	3.27	—	—	—
	—	-9.42	-13.10	—	—	—
	—	4.19	5.26	—	—	—
	—	11.13	15.70	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +14.48%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +15.67%
Profit YoY (TTM): -2,291.60%

Consolidated

Sales CAGR 3Y: +11.33%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +6.10%
Profit YoY (TTM): -294.44%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 58.46%

Quarter	30 Sep 2026	September 2026	June 2026
Promoter %	58.46%	58.46%	58.46%

Holder	Type	Holding	Previous	Change
IPCA LABORATORIES LIMITED	Promoter	40.45%	40.45%	0.00%
KUNAL NARENDRA GANDHI	Promoter	10.03%	10.03%	0.00%
NEHAL NARENDRA GANDHI	Promoter	3.60%	3.60%	0.00%
ENAI TRADING AND INVESTMENT PVT. LTD	Promoter Group	3.04%	3.04%	0.00%
THERMO CAPITAL PRIVATE LIMITED	Public	1.91%	1.91%	0.00%
PRANAY GODHA	Promoter	0.83%	0.83%	0.00%
ALISHA KUNAL GANDHI	Promoter Group	0.14%	0.14%	0.00%
SWETA SHAH	Promoter Group	0.11%	0.11%	0.00%
USHMA RONAK SHAH	Promoter Group	0.09%	0.09%	0.00%
LYKA GENERICS LIMITED	Promoter Group	0.06%	0.06%	0.00%
NEETU GODHA	Promoter	0.03%	0.03%	0.00%
PREMCHAND GODHA	Promoter	0.03%	0.03%	0.00%
USHA GODHA	Promoter	0.03%	0.03%	0.00%
BHAWNA GODHA	Promoter	0.02%	0.02%	0.00%
HIRALAXMI MULTITRADE PRIVATE	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Lyka Labs Ltd.	275	76.00	-56.09	-7.00%	+6.10% TTM	-294.44% TTM	-19.92%

Filings & corporate actions

Recent announcements

Revised intimation of NSE Notice for imposition of FIne3 Nov 2026 · Company Update / General
Intimation of NSE Notice and imposition of Fine2 Nov 2026 · Company Update / General
As per the letter attached31 Oct 2026 · Company Update / Newspaper Publication
As per the letter attached30 Oct 2026 · Company Update / Change in Directorate
As per the letter attached30 Oct 2026 · Company Update / Change in Management
As per the letter attached30 Oct 2026 · Result / Financial Results
As peer the letter attached30 Oct 2026 · Company Update / General
As per the letter attached30 Oct 2026 · Board Meeting / Outcome of Board Meeting
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve As per the letter attached14 Oct 2026 · Board Meeting / Board Meeting
As per the letter attached8 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the letter attached24 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
As per the letter attached12 Aug 2026 · Company Update / Newspaper Publication
As per the letter attached11 Aug 2026 · AGM/EGM / AGM
As per the letter attached11 Aug 2026 · Company Update / General
As per the letter attached10 Aug 2026 · AGM/EGM / AGM
As per the letter atatched10 Aug 2026 · Company Update / General
As per the letter attached10 Aug 2026 · Result / Financial Results
As per the letter attached10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve As per the letter attached24 Jul 2026 · Board Meeting / Board Meeting
As per the letter attached20 Jul 2026 · Company Update / Newspaper Publication
As per the letter attached17 Jul 2026 · AGM/EGM / AGM
As per the letter attached17 Jul 2026 · Company Update / General
As per the letter attached17 Jul 2026 · Others / Reg. 34 (1) Annual Report
As per the letter attached17 Jul 2026 · AGM/EGM / AGM
As per the letter attached10 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per the letter attached8 Jul 2026 · Company Update / Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & PACs30 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
As per the letter attached30 Jun 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & Others29 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
As per letter attached26 Jun 2026 · Company Update / General
As per letter attached24 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
As per the letter attached17 Jun 2026 · Company Update / General
As per the letter attached12 Jun 2026 · Company Update / Allotment of Equity Shares
Clarification on Price Movement11 Jun 2026 · Company Update / General
The Exchange has sought clarification from Lyka Labs Ltd on June 11, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....11 Jun 2026 · Company Update / Clarification
As per attachment4 Jun 2026 · Company Update / General
As per regulation 47 of the SEBI (LODR) Regulations, 2015 the extract of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2026 were published ....27 May 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance Report for the year ended 31.03.202626 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
As per the letter attached25 May 2026 · Result / Financial Results
As per the letter attached25 May 2026 · Board Meeting / Outcome of Board Meeting

Board meetings

30 Oct 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results